A Randomized, Double-Blind, Parallel Group Clinical Study to Evaluate the Efficacy and Safety of UO ABG 01 in the Management of Borderline Cardiovascular Risk Factors

The growing incidence of cardiovascular disease presents a substantial risk to developed and developing countries alike, thus necessitating prompt intervention.This clinical study was carried out to investigate the efficacy and safety of UO ABG 01, an aged black garlic extract containing 0.5% SAC and 2% polyphenol in the management of cardiovascular risk factors.In this randomized, double-blind, placebo-controlled study, 56 subjects at risk for cardiovascular factors were enrolled.Participants received either UO ABG 01 or placebo for 84 days.Serum triglycerides, serum HDL cholesterol, serum LDL cholesterol and total cholesterol were measured as the primary efficacy endpoints and fasting blood glucose and blood pressure were measured as secondary endpoints.UO ABG 01 supplementation significantly (p<0.05)reduced with a percentage reduction of 19.93% in serum triglycerides, 15.48% in serum LDL cholesterol, 13.45% in total cholesterol, 7.08% in systolic blood pressure, 8.34% in diastolic blood pressure and 11.67% in fasting blood glucose.Subjects in the UO ABG 01 group also reported significantly (p<0.05)greater improvement with 17.97% in serum HDL cholesterol.The findings of this study indicated that UO ABG 01 is an effective and safe alternative therapy for the treatment of cardiovascular disease (CVD).